Editors' ChoiceAlzheimer’s Disease

Reversing Decline?

See allHide authors and affiliations

Science Signaling  27 Mar 2012:
Vol. 5, Issue 217, pp. ec98
DOI: 10.1126/scisignal.2003067

Apolipoprotein E (apoE) normally helps in the clearance of β-amyloid (Aβ) from the brain, a process that is compromised in Alzheimer’s disease. Cramer et al. (see the Perspective by Strittmatter) now show that a drug that increases apoE expression rapidly promoted soluble Aβ clearance in a mouse model of Alzheimer’s disease. The drug also improved cognitive, social, and olfactory performance and rapidly improved neural circuit function. Similar therapeutics may potentially help to ameliorate the symptoms of Alzheimer’s disease and its prodromal states.

P. E. Cramer, J. R. Cirrito, D. W. Wesson, C. Y. D. Lee, J. C. Karlo, A. E. Zinn, B. T. Casali, J. L. Restivo, W. D. Goebel, M. J. James, K. R. Brunden, D. A. Wilson, G. E. Landreth, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506 (2012). [Abstract] [Full Text]

W. J. Strittmatter, Old drug, new hope for Alzheimer’s disease. Science 335, 1447–1448 (2012). [Abstract] [Full Text]

Stay Connected to Science Signaling